Spots Global Cancer Trial Database for advanced pancreatic cancer
Every month we try and update this database with for advanced pancreatic cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients | NCT04217096 | Advanced Pancre... | Paclitaxel lipo... S-1 | 18 Years - 75 Years | Fudan University | |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | NCT02135822 | Advanced Pancre... | nanoparticle al... gemcitabine | 18 Years - | Chinese PLA General Hospital | |
| Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia | NCT02267707 | Pancreatic Neop... Cholestasis | nab-paclitaxel Gemcitabine | 18 Years - | Celgene | |
| The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer | NCT05178628 | Pancreatic Canc... Thromboembolism | Innohep Chemotherapy: G... | 18 Years - | Institute of Molecular Medicine and Biomedical Research | |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer | NCT05298020 | Advanced Pancre... | Envafolimab Endostar Nab paclitaxel Gemcitabine | 18 Years - | The Affiliated Hospital of Xuzhou Medical University | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | NCT03435289 | Pancreatic Canc... Metastatic Panc... | CPI 613 in Comb... | 18 Years - | Atlantic Health System | |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer | NCT04803851 | Anlotinib Anti-PD-1 Antib... Advanced Pancre... | Anlotinib plus ... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | NCT00372944 | Pancreatic Canc... | AZD6244 capecitabine | 18 Years - | AstraZeneca | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer | NCT04239001 | Advanced Pancre... | PEG-rhG-CSF | 18 Years - 70 Years | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer | NCT02124317 | Advanced Pancre... | nanoparticle al... S-1 | 18 Years - | Chinese PLA General Hospital | |
| BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | NCT02650804 | Pancreatic Canc... | BPM31510 Nanosu... Gemcitabine | 18 Years - | Berg, LLC | |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer | NCT03435289 | Pancreatic Canc... Metastatic Panc... | CPI 613 in Comb... | 18 Years - | Atlantic Health System | |
| A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer | NCT01303172 | Advanced Pancre... | IMM-101 Gemcitabine | 18 Years - | Immodulon Therapeutics Ltd | |
| BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | NCT02650804 | Pancreatic Canc... | BPM31510 Nanosu... Gemcitabine | 18 Years - | Berg, LLC | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel | NCT02559674 | Advanced Pancre... | Gemcitabine Nab-paclitaxel ALT-803 | 18 Years - | Altor BioScience | |
| Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer | NCT00417976 | Pancreatic Canc... | Gemcitabine Bevacizumab Infusional 5-Fl... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | NCT00307723 | Pancreatic Canc... Pancreatic Duct... | bevacizumab 5-Fluorouracil Oxaliplatin gemcitabine External Beam R... | 18 Years - | Massachusetts General Hospital | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma | NCT04643405 | Advanced Pancre... | APG-1387 for In... Gemcitabine Nab paclitaxel | 18 Years - | Ascentage Pharma Group Inc. | |
| Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer | NCT00320749 | Pancreatic Canc... | Capecitabine Docetaxel Gemcitabine | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | NCT02179970 | Pancreatic Aden... Ovarian Serous ... Colorectal Canc... | Plerixafor | 16 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | NCT02718859 | Pancreatic Canc... | NK cells irreversible el... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Tumor Registry Pancreatic Cancer | NCT02089269 | Pancreas Cancer | 18 Years - | iOMEDICO AG | ||
| Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | NCT01010945 | Advanced Pancre... | erlotinib gemcitabine nab-paclitaxel | 18 Years - | Astellas Pharma Inc | |
| Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | NCT00789633 | Pancreatic Canc... | Masitinib Placebo Gemcitabine | 18 Years - | AB Science | |
| A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer | NCT03899649 | Stage III Pancr... | SOC NanoKnife Syste... | 18 Years - | Angiodynamics, Inc. | |
| Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma | NCT00744640 | Locally Advance... Metastatic Panc... | gemcitabine, ox... | 18 Years - | University Hospital, Basel, Switzerland | |
| Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer | NCT01048320 | Advanced Pancre... | Gemcitabine Oxaliplatin Imatinib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | NCT02718859 | Pancreatic Canc... | NK cells irreversible el... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | NCT04617067 | Advanced Pancre... | Paricalcitol Gemcitabine (GE... | 18 Years - | Cancer Trials Ireland | |
| Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen | NCT00417209 | Pancreatic Neop... | Larotaxel (XRP9... 5-Fluorouracil Capecitabine | 18 Years - | Sanofi | |
| Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer | NCT03837132 | Advanced Cancer | Palliative care... | 18 Years - | University of Manitoba | |
| Supportive Care Intervention-Pancreas | NCT01885884 | Advanced Pancre... | Embedded Suppor... | 18 Years - | University of Pittsburgh | |
| Tumor Registry Pancreatic Cancer | NCT02089269 | Pancreas Cancer | 18 Years - | iOMEDICO AG | ||
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | NCT02135822 | Advanced Pancre... | nanoparticle al... gemcitabine | 18 Years - | Chinese PLA General Hospital | |
| BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | NCT02650804 | Pancreatic Canc... | BPM31510 Nanosu... Gemcitabine | 18 Years - | Berg, LLC | |
| Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer | NCT03662035 | Advanced Pancre... | Apatinib S-1 | 18 Years - 70 Years | Changzhou No.2 People's Hospital | |
| Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer | NCT05916261 | Advanced Pancre... | Personalized ne... | 18 Years - | Ruijin Hospital | |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer | NCT04239001 | Advanced Pancre... | PEG-rhG-CSF | 18 Years - 70 Years | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer | NCT04239001 | Advanced Pancre... | PEG-rhG-CSF | 18 Years - 70 Years | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | |
| Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | NCT04931381 | Advanced Pancre... | Chemotherapy gu... | 18 Years - 80 Years | Changhai Hospital | |
| Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer | NCT05580445 | Advanced Pancre... | CT-707 Toripalimab Gemcitabine | 18 Years - 75 Years | Shouyao Holdings (Beijing) Co. LTD | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer | NCT04228601 | Advanced Pancre... | Fluzoparib Fluzoparib plac... mFOLFIRINOX | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies | NCT05028933 | Advanced Hepato... Advanced Colore... Advanced Gastri... Advanced Pancre... | EPCAM CAR-T | 18 Years - 70 Years | Zhejiang University | |
| Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene | NCT00386399 | Pancreatic Canc... | Mitomycin-C | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer | NCT05438797 | Advanced Pancre... | Adoptive TIL-TC... | 18 Years - 70 Years | Jinling Hospital, China | |
| Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | NCT04617067 | Advanced Pancre... | Paricalcitol Gemcitabine (GE... | 18 Years - | Cancer Trials Ireland | |
| Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | NCT02138383 | Pancreatic Canc... | Enzalutamide Gemcitabine Nab-paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients | NCT04217096 | Advanced Pancre... | Paclitaxel lipo... S-1 | 18 Years - 75 Years | Fudan University | |
| Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | NCT02703571 | Solid Tumors fo... Pancreatic Canc... Colorectal Canc... | ribociclib Trametinib | 18 Years - | Novartis | |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies | NCT05028933 | Advanced Hepato... Advanced Colore... Advanced Gastri... Advanced Pancre... | EPCAM CAR-T | 18 Years - 70 Years | Zhejiang University | |
| ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies | NCT05085548 | Advanced Pancre... Solid Tumor Mal... | ProAgio Dose Le... ProAgio Dose Le... ProAgio Dose Le... | 18 Years - | ProDa BioTech, LLC | |
| Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer | NCT03636308 | Pancreatic Canc... | nanoparticle al... S1 Gemcitabine | 18 Years - | Peking University | |
| Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer | NCT00515866 | Pancreatic Neop... | KU-0059436 (AZD... Gemcitabine | 18 Years - | AstraZeneca | |
| Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer | NCT00690300 | Pancreas Neopla... | Docetaxel Oxaliplatin | 18 Years - | University of Ulm | |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer | NCT05100329 | Advanced Pancre... | Mitoxantrone Hy... | 18 Years - 75 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer | NCT00789633 | Pancreatic Canc... | Masitinib Placebo Gemcitabine | 18 Years - | AB Science | |
| Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | NCT00640978 | Pancreatic Canc... | RAD001 Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer | NCT03415802 | Advanced Pancre... | Nab-paclitaxel ... | 18 Years - 75 Years | ChineseAMS | |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | NCT03331562 | Pancreatic Canc... Pancreas Adenoc... Advanced Pancre... Metastatic Panc... Metastatic Panc... | Pembrolizumab paricalcitol placebo | 18 Years - | Translational Genomics Research Institute | |
| A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer | NCT03899636 | Stage III Pancr... | Modified FOLFIR... NanoKnife Syste... | 18 Years - | Angiodynamics, Inc. | |
| Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | NCT02101580 | Advanced Pancre... | ADI-PEG 20 | 18 Years - | Polaris Group | |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | NCT03331562 | Pancreatic Canc... Pancreas Adenoc... Advanced Pancre... Metastatic Panc... Metastatic Panc... | Pembrolizumab paricalcitol placebo | 18 Years - | Translational Genomics Research Institute | |
| BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients | NCT02650804 | Pancreatic Canc... | BPM31510 Nanosu... Gemcitabine | 18 Years - | Berg, LLC | |
| A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | NCT04928625 | Advanced Pancre... | SHR-A1904 | 18 Years - 75 Years | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | NCT04931381 | Advanced Pancre... | Chemotherapy gu... | 18 Years - 80 Years | Changhai Hospital | |
| The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer | NCT05178628 | Pancreatic Canc... Thromboembolism | Innohep Chemotherapy: G... | 18 Years - | Institute of Molecular Medicine and Biomedical Research | |
| A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer | NCT04137536 | Pancreatic Canc... Advanced Pancre... Pancreatic Aden... Pancreatic Neop... | anti-EGFR-bispe... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer | NCT04931381 | Advanced Pancre... | Chemotherapy gu... | 18 Years - 80 Years | Changhai Hospital | |
| Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer | NCT02135822 | Advanced Pancre... | nanoparticle al... gemcitabine | 18 Years - | Chinese PLA General Hospital | |
| Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | NCT02138383 | Pancreatic Canc... | Enzalutamide Gemcitabine Nab-paclitaxel | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer | NCT06111274 | Advanced Pancre... | Pimicotinib (AB... | 18 Years - 75 Years | Abbisko Therapeutics Co, Ltd | |
| A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer | NCT03899649 | Stage III Pancr... | SOC NanoKnife Syste... | 18 Years - | Angiodynamics, Inc. | |
| AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | NCT00372944 | Pancreatic Canc... | AZD6244 capecitabine | 18 Years - | AstraZeneca | |
| A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | NCT04928625 | Advanced Pancre... | SHR-A1904 | 18 Years - 75 Years | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer | NCT03509298 | Advanced Pancre... | Activated CIK a... cryotherapy | 18 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | |
| Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer | NCT00320749 | Pancreatic Canc... | Capecitabine Docetaxel Gemcitabine | 18 Years - | Ohio State University Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
